ProShares UltraPro QQQ ETF (TQQQ) Stock Price Today
Aura AI Summary
Key Stats
- $34.01BMarket Cap
- 88,737,722Volume
- Leveraged / InverseSector
- $87.2252W High
- $37.8952W Low
- 26 DaysTypical Hold Time
- -Enterprise Value
- -Div Yield
- 84% Sell | 16% BuyTrading Activity
Track ProShares UltraPro QQQ ETF (TQQQ) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, ProShares UltraPro QQQ ETF has traded between a low of $37.89 and a high of $87.22, highlighting its annual price range. Buy and sell ProShares UltraPro QQQ ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Most Recent News
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.
The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Silence Therapeutics jumps 125% after $1.3B acquisition deal with Merck KGaA
Silence Therapeutics' stock surged 125.6% to $19.58 following Merck KGaA's agreement to acquire the RNA-interference drug developer for about $1.3 billion in equity value. Merck will pay $20 per share, a 130% premium over the recent closing price. Ot...

Stocks tumble as Iambic Therapeutics and TCGX Acquisition lead losses amid IPO and merger news.
On October 19, 2026, several stocks saw significant declines. Iambic Therapeutics dropped 31.4% but stayed just above its IPO price of $16 after raising $150 million. TCGX Acquisition fell 18.5% following its announcement of a merger with TriGemX Bio...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.